Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx2 LungVax
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx2 LungVax is an investigational cancer prevention vaccine developed by the University of Oxford in collaboration with the Francis Crick Institute and University College London. It utilizes a non-replicating chimpanzee adenovirus (ChAdOx2) viral vector platform—the same technology used in the Oxford/AstraZeneca COVID-19 vaccine—to deliver DNA encoding the cancer-associated antigens MAGE-A3 and NY-ESO-1. The vaccine is designed to prime the immune system to recognize and eliminate cells expressing these antigens, which are frequently found in lung cancer, thereby preventing the development or recurrence of non-small cell lung cancer (NSCLC). It is currently being evaluated in a Phase I clinical trial for patients with resected early-stage NSCLC.
- Other names
- LungVax
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on ChAdOx2 LungVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx2 LungVax.